| 32.65 0.09 (0.28%) | 01-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 50.35  |
1-year : | 58.01 |
| Resists | First : | 43.11 |
Second : | 49.66 |
| Pivot price | 38.98 |
|||
| Supports | First : | 32.5 | Second : | 27.04 |
| MAs | MA(5) : | 34.57 |
MA(20) : | 39.57 |
| MA(100) : | 56.21 |
MA(250) : | 57.62  |
|
| MACD | MACD : | -4 |
Signal : | -3.6 |
| %K %D | K(14,3) : | 5.5 |
D(3) : | 9.1 |
| RSI | RSI(14): 25.7 |
|||
| 52-week | High : | 99.41 | Low : | 20.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VKTX ] has closed above bottom band by 5.1%. Bollinger Bands are 6.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.27 - 34.51 | 34.51 - 34.7 |
| Low: | 32.12 - 32.37 | 32.37 - 32.56 |
| Close: | 32.33 - 32.71 | 32.71 - 33 |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Fri, 17 Jan 2025
Viking Therapeutics (NASDAQ:VKTX) Sees Strong Trading Volume - What's Next? - MarketBeat
Fri, 17 Jan 2025
Viking Therapeutics (NASDAQ:VKTX) Trading Down 4.8% - Here's What Happened - MarketBeat
Fri, 17 Jan 2025
Why Viking Therapeutics (VKTX) Is the Biotech Stock with Biggest Upside Potential - Yahoo Finance
Thu, 16 Jan 2025
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today - Benzinga
Tue, 14 Jan 2025
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX - PR Newswire
Mon, 13 Jan 2025
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 111 (M) |
| Shares Float | 105 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 75.9 (%) |
| Shares Short | 18,300 (K) |
| Shares Short P.Month | 16,990 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -12.7 % |
| Return on Equity (ttm) | -15.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -74 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -34.74 |
| PEG Ratio | 0 |
| Price to Book value | 3.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -49.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|